Form 4: Design Therapeutics Director Acquires Stock Options

Design Therapeutics Director Justin D. Gover acquired 30,000 stock options with an exercise price of $10.55 on June 9, 2026.

Summary

• Justin D. Gover, a Director at Design Therapeutics, Inc., acquired 30,000 stock options.
• The transaction occurred on June 9, 2026.
• The stock options have an exercise price of $10.55 per share.
• These options are exercisable and will expire on June 8, 2036.
• The underlying securities are 30,000 shares of common stock.
• The options vest in equal monthly installments over 12 months following June 9, 2026, with full vesting by the company's next annual meeting of stockholders.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, as it represents a standard insider grant of stock options with a vesting schedule, indicating continued engagement from a director.

Positives

• Director Justin D. Gover has acquired a significant number of stock options, indicating a potential belief in the company's future performance.
• The vesting schedule provides a long-term incentive for the director to remain with the company and contribute to its success.

Future Outlook

The stock options are set to vest over 12 months following June 9, 2026, with full vesting by the company's next annual meeting of stockholders, suggesting a continued commitment and incentive for the director.

Industry Context

StockSavvy.ai notes that insider transactions, such as the acquisition of stock options by directors, are common in the biotechnology and pharmaceutical sectors as a means to align executive interests with shareholder value and incentivize long-term growth.

Stakeholder Impact

• Shareholders: The acquisition of options by a director may be viewed positively, suggesting confidence in the company's future, but it does not immediately impact share price or ownership structure.

Next Steps

• The stock options will vest monthly over 12 months following June 9, 2026.
• Full vesting is expected by the company's next annual meeting of stockholders.

Key Dates

Keywords

Design Therapeutics, DSGN, Form 4, Stock Options, Insider Transaction, Director, Beneficial Ownership